Market Cap 70.82M
Revenue (ttm) 0.00
Net Income (ttm) -20.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.12
Volume 440,900
Avg Vol 743,880
Day's Range N/A - N/A
Shares Out 35.95M
Stochastic %K 63%
Beta 0.11
Analysts Strong Sell
Price Target $7.43

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 500 1556
Address:
4800 Montgomery Lane, Suite 220, Bethesda, United States
zamped1
zamped1 Oct. 25 at 9:25 PM
$GANX In my opinion the short increase from 9/30 to 10/15 is validation that a deal is happening. Many will think Im crazy but seen this movie before and it gives ne reasuurance that we all are on the right horse. Think this doesnt happen ? This is special powers at work keeping the price here so to buy this asset xheap as they can. It is my opinion and gives me added confidence that a deal will be struck within 5 months..My call....
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 5:53 PM
Enter: $GANX Calls Strike Price: $2 Expiry Date: NOV 21 2025 Buy in Price: $0.15 - $0.20 Sell Price: $0.27 Profit : +82% (Turn every $1 into $1.82) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
john_Ennis
john_Ennis Oct. 25 at 5:42 PM
$GANX have a good weekend everyone. Dont worry about current price. We have our data readout soon and the future looks bright. Relax. Its been a long journey but nearly heree hopefully.
0 · Reply
zamped1
zamped1 Oct. 25 at 2:41 AM
$GANX I believe this price action is done with intent....I will not elaborate much however many shares have traded and I believe this is likely to stay 1.90 to 2.10 by design...My call..could be very wrong....
3 · Reply
Jwa68
Jwa68 Oct. 24 at 10:11 PM
$GANX I could not be more genuinely pleased to see the below. While I question the authentcity of the increase being all truly shorted shares, I sincerely hope they are. In fact, by all means short more.. till your little heart is content. I simply think there is a high probability of a big surprise for some. Have a great weekend my friends.
1 · Reply
microcapspeculator
microcapspeculator Oct. 24 at 8:02 PM
$GANX In case we thought we were imagining all the shorting.
7 · Reply
billymike
billymike Oct. 24 at 7:00 PM
$GANX please leave us alone scumbags, thank you
1 · Reply
Tiny_Timm
Tiny_Timm Oct. 24 at 6:05 PM
$GANX if this GT02287 gets approved the drug will sell about $60MN a month from 1st month of sale. So why the price 1 month revenue?, risk adjusted should be higher if these biomarkers are even half good, which seems highly likely they are.
2 · Reply
gatorsgrip
gatorsgrip Oct. 24 at 5:43 PM
$GANX Still in an uptrend, close above 2$ were good. Money flow is close to oversold. Could get interesting next week.--IMO
0 · Reply
NearEyeOptic
NearEyeOptic Oct. 24 at 5:37 PM
$GANX is there $1 million prize for this sitting at two dollars at the end of the day?😂😂😂
1 · Reply
Latest News on GANX
Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct 16, 2025, 7:00 AM EDT - 9 days ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit


Gain Therapeutics Announces Proposed Public Offering

Jul 15, 2025, 4:36 PM EDT - 3 months ago

Gain Therapeutics Announces Proposed Public Offering


Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 28, 2025, 8:30 AM EDT - 7 months ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025


Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Mar 6, 2025, 7:55 AM EST - 8 months ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025


Gain Therapeutics To Present At Biotech Showcase 2025

Dec 11, 2024, 8:30 AM EST - 11 months ago

Gain Therapeutics To Present At Biotech Showcase 2025


Gain Therapeutics, Inc. (GANX) Special Call Transcript

Jul 1, 2024, 10:13 AM EDT - 1 year ago

Gain Therapeutics, Inc. (GANX) Special Call Transcript


Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Jun 27, 2024, 4:08 PM EDT - 1 year ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO


Gain Therapeutics to Present at Public Ventures Discovery Day

Mar 15, 2024, 2:30 PM EDT - 1 year ago

Gain Therapeutics to Present at Public Ventures Discovery Day


zamped1
zamped1 Oct. 25 at 9:25 PM
$GANX In my opinion the short increase from 9/30 to 10/15 is validation that a deal is happening. Many will think Im crazy but seen this movie before and it gives ne reasuurance that we all are on the right horse. Think this doesnt happen ? This is special powers at work keeping the price here so to buy this asset xheap as they can. It is my opinion and gives me added confidence that a deal will be struck within 5 months..My call....
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 5:53 PM
Enter: $GANX Calls Strike Price: $2 Expiry Date: NOV 21 2025 Buy in Price: $0.15 - $0.20 Sell Price: $0.27 Profit : +82% (Turn every $1 into $1.82) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
john_Ennis
john_Ennis Oct. 25 at 5:42 PM
$GANX have a good weekend everyone. Dont worry about current price. We have our data readout soon and the future looks bright. Relax. Its been a long journey but nearly heree hopefully.
0 · Reply
zamped1
zamped1 Oct. 25 at 2:41 AM
$GANX I believe this price action is done with intent....I will not elaborate much however many shares have traded and I believe this is likely to stay 1.90 to 2.10 by design...My call..could be very wrong....
3 · Reply
Jwa68
Jwa68 Oct. 24 at 10:11 PM
$GANX I could not be more genuinely pleased to see the below. While I question the authentcity of the increase being all truly shorted shares, I sincerely hope they are. In fact, by all means short more.. till your little heart is content. I simply think there is a high probability of a big surprise for some. Have a great weekend my friends.
1 · Reply
microcapspeculator
microcapspeculator Oct. 24 at 8:02 PM
$GANX In case we thought we were imagining all the shorting.
7 · Reply
billymike
billymike Oct. 24 at 7:00 PM
$GANX please leave us alone scumbags, thank you
1 · Reply
Tiny_Timm
Tiny_Timm Oct. 24 at 6:05 PM
$GANX if this GT02287 gets approved the drug will sell about $60MN a month from 1st month of sale. So why the price 1 month revenue?, risk adjusted should be higher if these biomarkers are even half good, which seems highly likely they are.
2 · Reply
gatorsgrip
gatorsgrip Oct. 24 at 5:43 PM
$GANX Still in an uptrend, close above 2$ were good. Money flow is close to oversold. Could get interesting next week.--IMO
0 · Reply
NearEyeOptic
NearEyeOptic Oct. 24 at 5:37 PM
$GANX is there $1 million prize for this sitting at two dollars at the end of the day?😂😂😂
1 · Reply
Dingo2
Dingo2 Oct. 24 at 5:14 PM
$GANX took a starter bite of this quiet one 🤙
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 24 at 4:00 PM
Enter: $GANX NOV 21 2025 $2 CALLS Buy in Price: $0.20 - $0.20 Take Profit: $0.36 Stop Bleeding: $0.18 ROI Potential: 82% https://moneygroup.us/
1 · Reply
Son_of_Liberty1776
Son_of_Liberty1776 Oct. 24 at 2:54 PM
$GANX added $1.99. Averaged up.
0 · Reply
mwb1
mwb1 Oct. 24 at 1:47 PM
$GANX Good chance we go higher today. $2.20? Let’s see how it plays out, but I’m also ready to buy significant dips.
2 · Reply
billymike
billymike Oct. 24 at 1:31 PM
$GANX guess they are going to play games all day. Everyone have great weekend!
0 · Reply
PaulWalter
PaulWalter Oct. 24 at 12:46 PM
$GANX This thing just doesn‘t want to move . Strange really. When you compare with other prerev bios with good potential it doesn't make sense. Manipulation only goes so far.
2 · Reply
Jwa68
Jwa68 Oct. 24 at 11:34 AM
$GANX National MJFF commercials, Washington Post article, and now Cantor holding KOL events and issuing notes, all about Parkinson’s. National epidemic and a primary focus of all large pharma. EVERY one of them per my former top pharma executives comments I shared yesterday. They are all surely at the table, $1B for the first disease modifying drug for PD and likely a host of other neurodegenerative diaeases. is a mere rounding error for all of them. Patent cliff approaching and pipelines thin, against a now improving macro biotech market. Look for a flurry of M&A imo.
1 · Reply
billymike
billymike Oct. 24 at 11:33 AM
$GANX hello all. Can we be done with the silly little games today. Thanks.
0 · Reply
DonkeyClanbrands
DonkeyClanbrands Oct. 24 at 10:38 AM
$GANX with a little Chat GPT help If GT-02287 shows strong biomarker/CSF proof of mechanism (increasing GCase, demonstrating CNS target engagement) and good safety/tolerability, it could de-risk the program significantly and elevate valuation. Neurodegeneration (especially Parkinson’s) is a large market with unmet need — if they can demonstrate a meaningful disease-modifying effect, the upside could be very large. Platform leverage: success of lead asset + platform could spawn multiple programs (rare lysosomal storage diseases, Alzheimer’s, etc) — meaning your investment could benefit from more than just one trial.
2 · Reply
microcapspeculator
microcapspeculator Oct. 24 at 12:53 AM
$GANX Saw this chart in the recent Oppenheimer report. Not much in the CNS space. A lot of money in the space. We could be in phase 2 in the near future. Or at least someone will.
2 · Reply
NearEyeOptic
NearEyeOptic Oct. 23 at 9:54 PM
$GANX less than 2$? A conundrum wrapped in an enigma wrapped in a pigs-in-a-blanket.😂😂😂
1 · Reply
marvessa
marvessa Oct. 23 at 8:02 PM
$GANX bothered , who keeps them downn?
0 · Reply